Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority
Executive Summary
NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.
You may also be interested in...
Asia Deal Watch: Innovent Picks Up Asian Rights To Three Clinical Cancer Candidates From Incyte
Incyte gets $40m up front and can earn up to $351.5m in milestones pegged to a Phase III JAK1 inhibitor and a pair of Phase II candidates. Shionogi obtains Asian rights to an allosteric inhibitor for cognitive disorders from Tetra.
Nicox PursuesTransformation Into Ophthalmic Specialty Company – And Partner
Nicox of France pins hopes on glaucoma drug Vesneo – targeted for FDA submission in second quarter 2015 – and recent purchase of Aciex Therapeutics to build itself into an international ophthalmic player and ‘partner of choice’ in Europe.
Lumigan To Go By Ganfort In The EU
Allergan will market its glaucoma therapy Lumigan in the European Union under the trade name Ganfort